Key result
Preoperative GLP-1 RA use in elective lumbar spine surgery was associated with lower rates of pseudarthrosis at 1 year compared to non-users (6.54% vs. 8.53%; RR 0.79; 95% CI 0.66-0.95; p<0.05).
Why the study?
The impact of preoperative GLP-1 receptor agonists on lumbar spine-specific postoperative outcomes remains underexplored despite their efficacy in glycemic control and weight loss.
Does preoperative GLP-1 RA use improve postoperative outcomes in patients undergoing elective lumbar spine surgery?
Cohort (n=5,722)
Yes
Does preoperative GLP-1 RA use improve postoperative outcomes in patients undergoing elective lumbar spine surgery?
Relative Risk: 0.79 (95% CI 0.66–0.95)
Absolute Event Rate: 6.54% vs 8.53%
p-value: p=< 0.05
Preoperative GLP-1 RA use in patients undergoing elective lumbar spine surgery is safe and associated with reduced rates of pseudarthrosis at 1 and 3 years.
Hypothesis-generating for GLP-1 RA benefit in spinal fusion; should not yet change practice pending randomized evidence.
Background: Obesity and diabetes mellitus are well documented to to elevate perioperative risks in spine surgery; hence, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained popularity due to their efficacy in improving glycemic control and weight loss. However, their impact on lumbar spine-specific outcomes remains underexplored. This study evaluates associations between preoperative GLP-1 RA use and postoperative outcomes in patients undergoing elective lumbar spine surgery. Methods: A retrospective cohort analysis of 5722 patients undergoing elective lumbar spine surgery was conducted using data from the TriNetX database. Patients were categorized into two cohorts: (1) GLP-1 RA users, defined by a documented prescription within six months prior to surgery, and (2) non-users. The cohorts were matched in a 1:1 ratio via propensity score matching based on age, BMI, diabetes status, and relevant comorbidities. Outcomes assessed included major medical complications within 90 days and mechanical complications (pseudarthrosis, foot drop, post-laminectomy syndrome, and reoperation rates) at 1- and 3-year follow-up intervals. Results: No significant differences were observed between the GLP-1 RA and control cohorts regarding rates of medical complications within the 90-day postoperative period. However, concerning mechanical complications, GLP-1 RA users demonstrated significantly lower rates of pseudarthrosis at 1 year (6.54% vs. 8.53%; RR: 0.79; 95% CI: 0.66-0.95; p < 0.05), an effect that persisted through the 3-year follow-up (8.88% vs. 10.77%; RR: 0.85; 95% CI: 0.73-0.99; p < 0.05). No statistically significant differences were observed in reoperation rates or other mechanical complications at either the 1-year or 3-year follow-up intervals. Conclusion: Preoperative GLP-1 RA use was not associated with increased short- or intermediate-term medical or mechanical complications following lumbar spine procedures. Notably, GLP-1 RA use correlated with reduced rates of pseudarthrosis at 1- and 3-year intervals. These findings support the safety and potential benefits of GLP-1 RAs in metabolically high-risk patients undergoing elective lumbar spine surgery.
No takes yet. Share an insight, caveat, or question.
Tummala et al. (2025) conducted a cohort in elective lumbar spine surgery (n=5,722). GLP-1 receptor agonists vs. non-users was evaluated on pseudarthrosis at 1 year (RR 0.79, 95% CI 0.66-0.95, p=< 0.05). Preoperative GLP-1 RA use in elective lumbar spine surgery was associated with lower rates of pseudarthrosis at 1 year compared to non-users (6.54% vs. 8.53%; RR 0.79; 95% CI 0.66-0.95; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: